Latest Search
Quote
| Back Zoom + Zoom - | ||||
|
<Research>M Stanley Rates FOSUN PHARMA as Overweight With TP HKD32, Lifts Rev. Forecast
Recommend 3 Positive 5 Negative 2 |
||||
|
||||
|
Morgan Stanley issued a research report raising FOSUN PHARMA (02196.HK)'s revenue forecasts for 2026-28 by 3%, citing higher sales of innovative drugs and expected recurring licensing income of around RMB800 million per year. Expecting FOSUN PHARMA to achieve the net profit targets under its employee stock ownership plan for 2026-27, Morgan Stanley rated FOSUN PHARMA as Overweight, alongside a target price of HKD32. Auto-translated by AI This article was automatically translated by AI, the original language version should be considered the authoritative version. AASTOCKS.com Limited does not guarantee its accuracy or completeness and accepts no liability for any damages or losses arising from the use of this translation. More Details
AASTOCKS Financial News |
||||
Copied to Clipboard
 |
||||
